Corona Remedies Ltd declared a final dividend of ₹10 per share for the financial year 2025-26 at its 22nd Annual General Meeting held on July 09, 2026. The meeting, conducted via video conferencing, saw the approval of the audited financial statements for the year ended March 31, 2026, and the re-appointment of statutory auditors and directors. All nine proposed resolutions were passed with the requisite majority through remote e-voting and e-voting conducted during the meeting.

Key Resolutions Passed

The shareholders approved a final dividend of ₹10 per equity share, representing a 100% payout on the face value of ₹10 each for F.Y. 2025-26. The resolution received 100% of the votes cast in favour.

Appointments and Ratifications

The meeting resulted in the appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors and M/s. Dhara Patel, Company Secretary Firm, as Secretarial Auditors. Additionally, the remuneration payable to Cost Auditors for F.Y. 2026-27 was ratified.

Director Re-appointments

Mr. Nirav Mehta (DIN: 01644041) was re-appointed as a Director, having retired by rotation. Dr. Kirtikumar Mehta (DIN: 00385658) was re-appointed as Non-Executive Director and Chairman for a term of five years. The meeting also approved the payment of commission to Non-Executive Directors and remuneration to Dr. Kirtikumar Mehta for the Financial Year 2026-27.

Voting Results Summary

The remote e-voting facility was open from July 06, 2026 to July 08, 2026. The Scrutinizer's Report, issued by M/s. Dhara Patel, Company Secretary Firm, confirmed the results. The AGM commenced at 11:00 a.m. and concluded at 12:15 p.m.

Corona Remedies Limited has commenced commercial production at its newly inaugurated EU-GMP approved Women's Hormone manufacturing facility located in Bhayla, Ahmedabad. The development strengthens the company's capabilities to serve domestic and international markets with specialised high-quality pharmaceutical products. The facility was inaugurated by Dr. K. L. Mehta, Chairman, alongside long-serving women employees of the organisation.

The new manufacturing unit is spread across 1.0 lakh sq. ft and is designed to handle complex hormonal medicines, which require stringent contamination control and specialised containment technologies. It supports multiple dosage forms — including tablets, soft gel capsules, ointments, and gels — within a single specialised ecosystem.

Capacity and Technology

With the commissioning of this facility, Corona Remedies Limited's in-house hormone manufacturing capacity is expected to increase by nearly 20%. The plant incorporates next-generation manufacturing technologies and digital process controls to ensure product consistency and operational excellence. The following table outlines the key capacity metrics of the new facility:

Key capabilities include fully integrated closed-loop manufacturing systems supported by 21 CFR-compliant equipment and Quality by Design (QbD) principles. The facility also features advanced gelatin processing systems with precision-controlled agitation and jacketed vessels for accurate temperature management.

Strategic Importance

Mr. Nirav K. Mehta, Founder, Managing Director & CEO, stated that the dedicated hormone facility represents the company's commitment to delivering globally benchmarked quality. He emphasised that scientific innovation must be complemented by world-class manufacturing capabilities to ensure women have access to safe and reliable hormone therapies.

The establishment of this facility addresses the growing need for specialised manufacturing driven by increasing demand for fertility care, menopause management, and hormone replacement therapies.